Who
Nicholas Conrad Smith
President and CFO
Company insider
Files Form 4 as: President and CFO, Alto Neuroscience.
In numbers
- Trades disclosed
- 31
- Buys
- 2
- Sells
- 2
- Bought
- $126K
- Sold
- $3.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Feb 2024
- Last trade
- 2 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 5 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code M | $128K55,000 at $2.32 | filing |
| 2 Oct 2026filed 5 Oct 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 30 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code M | $57K24,056 at $2.35 | filing |
| 30 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Sold | $597K23,170 at $25.78 | filing |
| 30 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Sold | $24K886 at $26.87 | filing |
| 30 Sep 2026filed 1 Oct 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,056 at $0.00 | filing |
| 29 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code M | $133K56,455 at $2.35 | filing |
| 29 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code M | $128K54,375 at $2.35 | filing |
| 29 Sep 2026filed 1 Oct 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Sold | $2.9M110,830 at $26.58 | filing |
| 29 Sep 2026filed 1 Oct 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,455 at $0.00 | filing |
| 29 Sep 2026filed 1 Oct 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code M | —54,375 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code F | $55K2,806 at $19.69 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ANRO Alto NeuroscienceBiotechnology | SEC FORM 4 Code F | $55K2,806 at $19.69 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,962 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,962 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,833 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,833 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,329 | filing |
News
No headline names them, or the companies they trade most, lately.